Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18


Cathepsin B Is Dispensable for Cellular Processing of Cathepsin B-Cleavable Antibody-Drug Conjugates.

Caculitan NG, Dela Cruz Chuh J, Ma Y, Zhang D, Kozak KR, Liu Y, Pillow TH, Sadowsky J, Cheung TK, Phung Q, Haley B, Lee BC, Akita RW, Sliwkowski MX, Polson AG.

Cancer Res. 2017 Dec 15;77(24):7027-7037. doi: 10.1158/0008-5472.CAN-17-2391. Epub 2017 Oct 18.


High cell-surface density of HER2 deforms cell membranes.

Chung I, Reichelt M, Shao L, Akita RW, Koeppen H, Rangell L, Schaefer G, Mellman I, Sliwkowski MX.

Nat Commun. 2016 Sep 7;7:12742. doi: 10.1038/ncomms12742.


Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941.

Junttila TT, Akita RW, Parsons K, Fields C, Lewis Phillips GD, Friedman LS, Sampath D, Sliwkowski MX.

Cancer Cell. 2009 May 5;15(5):429-40. doi: 10.1016/j.ccr.2009.03.020. Erratum in: Cancer Cell. 2011 Dec 13;20(6):818.


Preclinical studies with Erlotinib (Tarceva).

Akita RW, Sliwkowski MX.

Semin Oncol. 2003 Jun;30(3 Suppl 7):15-24. Review. Erratum in: Semin Oncol. 2003 Dec;30(6):826.


Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth.

Agus DB, Akita RW, Fox WD, Lewis GD, Higgins B, Pisacane PI, Lofgren JA, Tindell C, Evans DP, Maiese K, Scher HI, Sliwkowski MX.

Cancer Cell. 2002 Aug;2(2):127-37.


Identification of a region within the ErbB2/HER2 intracellular domain that is necessary for ligand-independent association.

Penuel E, Akita RW, Sliwkowski MX.

J Biol Chem. 2002 Aug 9;277(32):28468-73. Epub 2002 May 8.


Structural requirements for ErbB2 transactivation.

Penuel E, Schaefer G, Akita RW, Sliwkowski MX.

Semin Oncol. 2001 Dec;28(6 Suppl 18):36-42. Review.


A potential role for activated HER-2 in prostate cancer.

Agus DB, Akita RW, Fox WD, Lofgren JA, Higgins B, Maiese K, Scher HI, Sliwkowski MX.

Semin Oncol. 2000 Dec;27(6 Suppl 11):76-83; discussion 92-100. Review.


Biologic effects of heregulin/neu differentiation factor on normal and malignant human breast and ovarian epithelial cells.

Aguilar Z, Akita RW, Finn RS, Ramos BL, Pegram MD, Kabbinavar FF, Pietras RJ, Pisacane P, Sliwkowski MX, Slamon DJ.

Oncogene. 1999 Oct 28;18(44):6050-62.


Binding specificities and affinities of egf domains for ErbB receptors.

Jones JT, Akita RW, Sliwkowski MX.

FEBS Lett. 1999 Mar 26;447(2-3):227-31.


Selection of heregulin variants having higher affinity for the ErbB3 receptor by monovalent phage display.

Ballinger MD, Jones JT, Lofgren JA, Fairbrother WJ, Akita RW, Sliwkowski MX, Wells JA.

J Biol Chem. 1998 May 8;273(19):11675-84.


Coexpression of erbB2 and erbB3 proteins reconstitutes a high affinity receptor for heregulin.

Sliwkowski MX, Schaefer G, Akita RW, Lofgren JA, Fitzpatrick VD, Nuijens A, Fendly BM, Cerione RA, Vandlen RL, Carraway KL 3rd.

J Biol Chem. 1994 May 20;269(20):14661-5.


Identification of heregulin, a specific activator of p185erbB2.

Holmes WE, Sliwkowski MX, Akita RW, Henzel WJ, Lee J, Park JW, Yansura D, Abadi N, Raab H, Lewis GD, et al.

Science. 1992 May 22;256(5060):1205-10.


An antigen immunologically related to the external domain of gp185 is shed from nude mouse tumors overexpressing the c-erbB-2 (HER-2/neu) oncogene.

Langton BC, Crenshaw MC, Chao LA, Stuart SG, Akita RW, Jackson JE.

Cancer Res. 1991 May 15;51(10):2593-8.


Serological evaluation of Escherichia coli-expressed human T-cell leukemia virus type I env, gag p24, and tax proteins.

Coates SR, Harris AJ, Parkes DL, Smith CM, Liu HL, Akita RW, Ferrer MM, Sampson EK, Brandis JW, Sliwkowski MX.

J Clin Microbiol. 1990 Jun;28(6):1139-42.

Supplemental Content

Loading ...
Support Center